Brain Ketone Metabolism in Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 14, 2013

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Type 1 DiabetesHypoglycemia
Interventions
DRUG

Beta-hydroxybutyrate

Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.

OTHER

Normal Saline

Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.

Trial Locations (1)

06510

Yale New Haven Hospital, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT02471040 - Brain Ketone Metabolism in Type 1 Diabetes | Biotech Hunter | Biotech Hunter